Protective effect of microbisporicin (NAI-107) against vancomycin resistant Enterococcus faecium infection in a Galleria mellonella model
- PMID: 38413672
- PMCID: PMC10899196
- DOI: 10.1038/s41598-024-55262-8
Protective effect of microbisporicin (NAI-107) against vancomycin resistant Enterococcus faecium infection in a Galleria mellonella model
Abstract
Increasing antimicrobial resistance in Enterococcus faecium necessitates the search for novel treatment agents, such as bacteriocins. In this study, we conducted an in vivo assessment of five bacteriocins, namely Lacticin Z, Lacticin Q, Garvicin KS (ABC), Aureocin A53 and Microbisporicin (NAI-107), against vanB-resistant Enterococcus faecium using a Galleria mellonella model. Our in vitro experiments demonstrated the efficacy of all five bacteriocins against vanB-resistant E. faecium with only NAI-107 demonstrating in vivo efficacy. Notably, NAI-107 exhibited efficacy across a range of tested doses, with the highest efficacy observed at a concentration of 16 µg/mL. Mortality rates in the group treated with 16 µg/mL NAI-107 were lower than those observed in the linezolid-treated group. These findings strongly suggest that NAI-107 holds promise as a potential alternative therapeutic agent for treating infections caused by resistant E. faecium and warrants further investigation.
Keywords: Enterococcus faecium; Galleria mellonella; Lantibiotics; Microbisporicin; NAI-107; VanB.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures



Similar articles
-
Microbisporicin (NAI-107) protects Galleria mellonella from infection with Neisseria gonorrhoeae.Microbiol Spectr. 2023 Dec 12;11(6):e0282523. doi: 10.1128/spectrum.02825-23. Epub 2023 Oct 12. Microbiol Spectr. 2023. PMID: 37823634 Free PMC article.
-
Enterococcus faecium Bacteriophage vB_EfaH_163, a New Member of the Herelleviridae Family, Reduces the Mortality Associated with an E. faecium vanR Clinical Isolate in a Galleria mellonella Animal Model.Viruses. 2023 Jan 7;15(1):179. doi: 10.3390/v15010179. Viruses. 2023. PMID: 36680219 Free PMC article.
-
The LiaFSR-LiaX System Mediates Resistance of Enterococcus faecium to Peptide Antibiotics and to Aureocin A53- and Enterocin L50-Like Bacteriocins.Microbiol Spectr. 2023 Jun 15;11(3):e0034323. doi: 10.1128/spectrum.00343-23. Epub 2023 May 23. Microbiol Spectr. 2023. PMID: 37219451 Free PMC article.
-
Treatment options for vancomycin-resistant enterococcal infections.Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002. Drugs. 2002. PMID: 11827558 Review.
-
Vancomycin-resistant Enterococcus faecium and the emergence of new sequence types associated with hospital infection.Res Microbiol. 2023 May;174(4):104046. doi: 10.1016/j.resmic.2023.104046. Epub 2023 Feb 27. Res Microbiol. 2023. PMID: 36858192 Review.
Cited by
-
The clinical praxis of bacteriocins as natural anti-microbial therapeutics.Arch Microbiol. 2024 Oct 30;206(11):451. doi: 10.1007/s00203-024-04152-8. Arch Microbiol. 2024. PMID: 39476181 Review.
-
Multiplexed bacteriocin synthesis to combat and prevent antimicrobial resistance.Commun Biol. 2025 Aug 19;8(1):1246. doi: 10.1038/s42003-025-08639-y. Commun Biol. 2025. PMID: 40830650 Free PMC article.
References
-
- Hidron AI, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect. Control Hosp. Epidemiol. 2008;29(11):996–1011. doi: 10.1086/591861. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources